en
Scientific article
Open access
English

Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience

Published inInternational journal of radiation oncology, biology, physics, vol. 58, no. 5, p. 1431-1436
Publication date2004
Abstract

Accelerated schedules are effective in overcoming repopulation during radiotherapy (RT) for head-and-neck cancers, but their feasibility is compromised by increased toxicity. The therapeutic ratio may be particularly favorable for 5-week regimens. This study reports the 10-year experience of a single institution in the routine use of concomitant boost RT as standard radical treatment in all but the most favorable stage patients.

Keywords
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Carcinoma, Squamous Cell/drug therapy/radiotherapy/surgery
  • Cause of Death
  • Cisplatin/administration & dosage
  • Combined Modality Therapy
  • Dose Fractionation
  • Feasibility Studies
  • Female
  • Fluorouracil/administration & dosage
  • Head and Neck Neoplasms/drug therapy/radiotherapy/surgery
  • Humans
  • Male
  • Middle Aged
  • Statistics as Topic
Citation (ISO format)
ALLAL, Abdelkarim Said et al. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. In: International journal of radiation oncology, biology, physics, 2004, vol. 58, n° 5, p. 1431–1436. doi: 10.1016/j.ijrobp.2003.09.017
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0360-3016
523views
474downloads

Technical informations

Creation10/28/2013 8:25:00 PM
First validation10/28/2013 8:25:00 PM
Update time03/14/2023 8:50:10 PM
Status update03/14/2023 8:50:09 PM
Last indexation01/16/2024 8:50:23 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack